News | April 06, 2026
Red Nucleus acquires Bridge Medical Consulting with advisory support from VERTICES PARTNERS
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
He brings extensive cross-functional expertise built through leadership roles
With more than two decades of experience, he brings deep expertise in sales, marketing, business transformation, and strategic leadership
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Company leadership is framing the move as transformational.
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Subscribe To Our Newsletter & Stay Updated
